Modality
Gene Therapy
MOA
HER2
Target
TIM-3
Pathway
Lipid Met
Ovarian Ca
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ Oct 2027
Phase 1Current
NCT06527592
1,282 pts·Ovarian Ca
2017-09→2027-08·Active
NCT05317566
623 pts·Ovarian Ca
2017-04→2027-10·Recruiting
1,905 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-011.3y awayPh2 Data· Ovarian Ca
2027-10-201.6y awayPh2 Data· Ovarian Ca
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2027-08-01 · 1.3y away
Ovarian Ca
Ph2 Data
2027-10-20 · 1.6y away
Ovarian Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06527592 | Phase 1/2 | Ovarian Ca | Active | 1282 | EDSS |
| NCT05317566 | Phase 1/2 | Ovarian Ca | Recruiting | 623 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |